Intra-tumoral activation of AKT has been correlated with resistance to multiple classes of inhibitors including EGFR inhibitors, estrogen receptor antagonists and aromatase antagonists in breast cancer and anti-hormone therapies in prostate cancer11–13. The gene discussed is AKT1; the disease is breast carcinoma.